VERU INC. Amortization of Intangible Assets
VERU INC. (VERU) reported Amortization of Intangible Assets of $71.00 thousand for the 12-month period ending 2023-09-30, per its 10-K/A filed 2024-04-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2024-04-01
- VERU INC. amortization of intangible assets for the quarter ending 2023-09-30 was $17.00K, a 0.00% change year-over-year.
- VERU INC. amortization of intangible assets for the quarter ending 2023-06-30 was $18.00K, a 0.00% change year-over-year.
- VERU INC. amortization of intangible assets for the quarter ending 2023-03-31 was $18.00K, a 0.00% change year-over-year.
- VERU INC. amortization of intangible assets for the quarter ending 2022-12-31 was $18.00K, a 0.00% change year-over-year.
- VERU INC. amortization of intangible assets for fiscal 2023 was $71.00K, a 0.00% change from fiscal 2022.
- VERU INC. amortization of intangible assets for fiscal 2022 was $71.00K, a 37.17% decline from fiscal 2021.
- VERU INC. amortization of intangible assets for fiscal 2021 was $113.00K, a 64.24% decline from fiscal 2020.
- VERU INC. amortization of intangible assets for fiscal 2020 was $316.00K, a 2.19% increase from fiscal 2019.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 3 month as first filed | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 6 month as first filed | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 9 month as first filed | Amortization of Intangible Assets 12 month | Amortization of Intangible Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2023-09-30 | $17.00K derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2024-04-01 | $35.00K derived: sum of 2 quarters · filed 2024-04-01 | $53.00K derived: sum of 3 quarters · filed 2024-04-01 | $71.00K 10-K/A · filed 2024-04-01 | ||||
| 2023-06-30 | $18.00K 10-Q/A · filed 2023-11-15 | $36.00K derived: sum of 2 quarters · filed 2023-11-15 | $54.00K 10-Q/A · filed 2023-11-15 | $71.00K derived: sum of 4 quarters · filed 2024-04-01 | ||||
| 2023-03-31 | $18.00K 10-Q · filed 2023-05-11 | $36.00K 10-Q · filed 2023-05-11 | $53.00K derived: sum of 3 quarters · filed 2024-04-01 | $71.00K derived: sum of 4 quarters · filed 2024-04-01 | ||||
| 2022-12-31 | $18.00K 10-Q · filed 2023-02-09 | $35.00K derived: sum of 2 quarters · filed 2024-04-01 | $53.00K derived: sum of 3 quarters · filed 2024-04-01 | $71.00K derived: sum of 4 quarters · filed 2024-04-01 | ||||
| 2022-09-30 | $17.00K derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2024-04-01 | $35.00K derived: sum of 2 quarters · filed 2024-04-01 | $53.00K derived: sum of 3 quarters · filed 2024-04-01 | $71.00K 10-K/A · filed 2024-04-01 | ||||
| 2022-06-30 | $18.00K 10-Q/A · filed 2023-11-15 | $36.00K derived: sum of 2 quarters · filed 2023-11-15 | $54.00K 10-Q/A · filed 2023-11-15 | $71.00K derived: sum of 4 quarters · filed 2023-11-15 | ||||
| 2022-03-31 | $18.00K 10-Q · filed 2023-05-11 | $36.00K 10-Q · filed 2023-05-11 | $53.00K derived: sum of 3 quarters · filed 2023-05-11 | $71.00K derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $18.00K 10-Q · filed 2023-02-09 | $35.00K derived: sum of 2 quarters · filed 2023-02-09 | $53.00K derived: sum of 3 quarters · filed 2023-02-09 | $71.00K derived: sum of 4 quarters · filed 2023-02-09 | ||||
| 2021-09-30 | $17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-12-05 | $35.00K derived: sum of 2 quarters · filed 2022-12-05 | $53.00K derived: sum of 3 quarters · filed 2022-12-05 | $113.00K 10-K · filed 2022-12-05 | ||||
| 2021-06-30 | $18.00K 10-Q · filed 2022-08-11 | $36.00K derived: sum of 2 quarters · filed 2022-08-11 | $96.00K 10-Q · filed 2022-08-11 | $175.00K derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $18.00K 10-Q · filed 2022-05-12 | $78.00K 10-Q · filed 2022-05-12 | $157.00K derived: sum of 3 quarters · filed 2022-05-12 | $236.00K derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $60.00K 10-Q · filed 2022-02-09 | $139.00K derived: sum of 2 quarters · filed 2022-02-09 | $218.00K derived: sum of 3 quarters · filed 2022-02-09 | $297.00K derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-09-30 | $79.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-02 | $158.00K derived: sum of 2 quarters · filed 2021-12-02 | $237.00K derived: sum of 3 quarters · filed 2021-12-02 | $316.00K 10-K · filed 2021-12-02 | $316.37K 10-K · filed 2020-12-10 | |||
| 2020-06-30 | $79.00K 10-Q · filed 2021-08-12 | $158.00K derived: sum of 2 quarters · filed 2021-08-12 | $237.00K 10-Q · filed 2021-08-12 | $237.28K 10-Q · filed 2020-08-13 | $314.31K derived: sum of 4 quarters · filed 2021-08-12 | |||
| 2020-03-31 | $79.00K 10-Q · filed 2021-05-12 | $158.00K 10-Q · filed 2021-05-12 | $158.18K 10-Q · filed 2020-05-13 | $235.31K derived: sum of 3 quarters · filed 2021-05-12 | $312.31K derived: sum of 4 quarters · filed 2021-05-12 | |||
| 2019-12-31 | $79.00K 10-Q · filed 2021-02-10 | $79.09K 10-Q · filed 2020-02-12 | $156.31K derived: sum of 2 quarters · filed 2021-02-10 | $233.31K derived: sum of 3 quarters · filed 2021-02-10 | $310.31K derived: sum of 4 quarters · filed 2021-02-10 | |||
| 2019-09-30 | $77.31K derived: 10-K 12 month − 10-Q 9 month · filed 2020-12-10 | $154.31K derived: sum of 2 quarters · filed 2020-12-10 | $231.31K derived: sum of 3 quarters · filed 2020-12-10 | $309.23K 10-K · filed 2020-12-10 | ||||
| 2019-06-30 | $77.00K 10-Q · filed 2020-08-13 | $154.00K derived: sum of 2 quarters · filed 2020-08-13 | $231.93K 10-Q · filed 2020-08-13 | $300.12K derived: sum of 4 quarters · filed 2020-08-13 | ||||
| 2019-03-31 | $77.00K 10-Q · filed 2020-05-13 | $154.62K 10-Q · filed 2020-05-13 | $223.12K derived: sum of 3 quarters · filed 2020-05-13 | $292.12K derived: sum of 4 quarters · filed 2020-05-13 | ||||
| 2018-12-31 | $77.31K 10-Q · filed 2020-02-12 | $146.12K derived: sum of 2 quarters · filed 2020-02-12 | $215.12K derived: sum of 3 quarters · filed 2020-02-12 | $284.12K derived: sum of 4 quarters · filed 2020-02-12 | ||||
| 2018-09-30 | $68.81K derived: 10-K 12 month − 10-Q 9 month · filed 2019-12-12 | $137.81K derived: sum of 2 quarters · filed 2019-12-12 | $206.81K derived: sum of 3 quarters · filed 2019-12-12 | $275.26K 10-K · filed 2019-12-12 | ||||
| 2018-06-30 | $69.00K 10-Q · filed 2019-08-08 | $138.00K derived: sum of 2 quarters · filed 2019-08-08 | $206.45K 10-Q · filed 2019-08-08 | $246.91K derived: sum of 4 quarters · filed 2019-08-08 | ||||
| 2018-03-31 | $69.00K 10-Q · filed 2019-05-15 | $137.63K 10-Q · filed 2019-05-15 | $177.91K derived: sum of 3 quarters · filed 2019-05-15 | $217.91K derived: sum of 4 quarters · filed 2019-05-15 | ||||
| 2017-12-31 | $68.82K 10-Q · filed 2019-02-13 | $108.91K derived: sum of 2 quarters · filed 2019-02-13 | $148.91K derived: sum of 3 quarters · filed 2019-02-13 | $188.91K derived: sum of 4 quarters · filed 2019-02-13 | ||||
| 2017-09-30 | $40.09K derived: 10-K 12 month − 10-Q 9 month · filed 2018-12-13 | $80.09K derived: sum of 2 quarters · filed 2018-12-13 | $120.09K derived: sum of 3 quarters · filed 2018-12-13 | $147.01K 10-K · filed 2018-12-13 | ||||
| 2017-06-30 | $40.00K 10-Q · filed 2018-08-14 | $40.09K 10-Q · filed 2017-08-09 | $80.00K derived: sum of 2 quarters · filed 2018-08-14 | $106.92K 10-Q · filed 2018-08-14 | ||||
| 2017-03-31 | $40.00K 10-Q · filed 2018-05-11 | $40.09K 10-Q · filed 2017-05-10 | $66.82K 10-Q · filed 2018-05-11 | |||||
| 2016-12-31 | $26.73K 10-Q · filed 2018-02-14 | |||||||
| 2016-06-30 | $0.00 10-Q · filed 2017-08-09 | $0.00 derived: sum of 2 quarters · filed 2017-08-09 | $0.00 10-Q · filed 2017-08-09 | |||||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-10 | $0.00 10-Q · filed 2017-05-10 | ||||||
| 2015-12-31 | $0.00 10-Q · filed 2017-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |